Jill Quiambao
Family · Mineola, TXNPI 1265583504
Payments from drug & device makers
Across 104 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$245
- Pfizer$225
- Novo Nordisk$210
- Johnson & Johnson$207
- Myriad Genetic Laboratories, Inc.$175
- GSK$172
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,27392%
- Education$1988%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $245 |
| Pfizer | 4 | $225 |
| Novo Nordisk | 12 | $210 |
| Johnson & Johnson | 7 | $207 |
| Myriad Genetic Laboratories, Inc. | 3 | $175 |
| GSK | 10 | $172 |
| Novartis | 6 | $143 |
| AVEO Pharmaceuticals, Inc. | 3 | $140 |
| Genentech USA, Inc. | 4 | $92 |
| Amgen | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Lilly USA, LLC | 4 | $61 |
| Exact Sciences | 4 | $57 |
| Exelixis Inc. | 3 | $54 |
| Geron Corporation | 2 | $53 |
| AbbVie | 2 | $42 |
| Incyte Corporation | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $20 |
| Merck | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$109
- PREVNAR 20$106
- COMIRNATY$106
- ABRYSVO$106
How this compares
$2,471 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 32 | $52,031 |
| JardianceEmpagliflozin | 40 | $35,828 |
| TrulicityDulaglutide | 18 | $18,004 |
| MyrbetriqMirabegron | 16 | $11,583 |
| EliquisApixaban | 15 | $10,778 |
| OzempicSemaglutide | 11 | $9,416 |
| PremarinEstrogens, Conjugated | 15 | $4,217 |
| SynthroidLevothyroxine Sodium | 41 | $3,315 |
| Irbesartan | 171 | $2,551 |
| Trazodone Hcl | 155 | $2,217 |
| Levothyroxine Sodium | 292 | $2,164 |
| Rosuvastatin Calcium | 180 | $1,893 |
| Atorvastatin Calcium | 215 | $1,671 |
| Pantoprazole Sodium | 177 | $1,602 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $210 | $61,44743 claims |
| Lilly USA, LLCTrulicity | $61 | $18,00418 claims |
| PfizerEliquis, Premarin | $225 | $14,99530 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $11,58316 claims |
| AbbVieSynthroid | $42 | $3,31541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Mineola
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.